Kantar Health Blog

  • Patricia Ensor
    One concern about the Affordable Care Act (ACA) is that it may cause an influx of unhealthy patients into the healthcare market, overwhelming an already taxed system. Are these people taking better care of themselves? How do they feel about health, and how will this affect their use of healthcare resources once they are insured?
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GU --- Prostate cancer is the most common cancer in men and the second most common cause of cancer deaths in men in the United States. The incident population of prostate cancer in the United States was above 200,000 patients in 2013. The rate of prostate cancer growth varies from very slow to moderately rapid, and some patients may have prolonged survival even after the cancer has metastasized to distant sites such as bone.
    Continue Reading > | Go comment! | Share
  • Are the uninsured in America who we think they are?

    by Patricia Ensor | Jan 24, 2014
    Patricia Ensor
    The ACA’s critics fear the uninsured are less healthy than insured Americans, meaning premiums and healthcare costs would be higher for everyone. But is this really true?
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Oncology Conference Insight: ASCO GI 2014 --- Hepatocellular carcinoma (HCC) is a particularly challenging disease. Surgery remains the only curative strategy for patients with HCC, however not all patients are eligible for surgery. The approval of Nexavar® (sorafenib, Bayer/Onyx/Amgen) revolutionized HCC, providing a targeted therapy option for patients with HCC and an advance over de facto standard doxorubicin. The enthusiasm for Nexavar is dampened by the fact that not all patients may be eligible for Nexavar treatment due to poor liver function, and options remain limited for patients whose disease progresses.
    Continue Reading > | Go comment! | Share
  • I-SPY 2 Graduates its First Experimental Regimen

    by Stephanie Hawthorne | Dec 13, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- The I-SPY 2 trial is an innovative “find a winner” trial that aims to address some of these challenges by screening a number of different novel experimental agents in the neoadjuvant setting in combination with a standard chemotherapy regimen of paclitaxel followed by AC compared to standard chemotherapy alone. In this novel trial design, the randomization of patients to treatment arms is adaptive, with randomization probabilities continuing to be updated as the trial progressed.
    Continue Reading > | Go comment! | Share